From June 12 to June 15, hematology experts from around the world came together in Milan, Italy, for the European Hematology Association (EHA) 2025 Congress, marking the meeting's 30th anniversary ...

The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according to session ...

The data presented at EHA 2025 support the ongoing advancement of sonrotoclax and BGB-16673 into Phase 3 studies and lay the groundwork for BeOne’s first regulatory submissions for these programs.

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Provided by GlobeNewswire May 14, 2025, 1:30:00 PM ...

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY ®) Development Program at the 2025 European Hematology Association (EHA) Congress. Data from 14 abstracts highlight ...

Gilead Sciences, Inc. (NASDAQ:GILD) plans to present over 20 research abstracts—spanning both Gilead and its cell therapy unit Kite—at two major medical conferences: the 2025 ASCO Annual ...

(RTTNews) - BeOne Medicines Ltd. (ONC) Thursday announced it presented new clinical data at the 2025 European Hematology Association or EHA Congress, highlighting the potential of its next ...

These updated EAP results for 173 patients, to be presented at EHA Congress, are consistent with the positive topline results of the Phase 3 trial announced in January 2025 and further confirm ...

Legend Biotech Corporation announced new data regarding CARVYKTI® (ciltacabtagene autoleucel) at the upcoming ASCO and EHA Congresses, emphasizing its effectiveness in heavily pre-treated ...